Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Total Current Liabilities (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Total Current Liabilities for 16 consecutive years, with $133.8 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 18.46% to $133.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $133.8 million through Dec 2025, down 18.46% year-over-year, with the annual reading at $133.8 million for FY2025, 18.46% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $133.8 million at Myriad Genetics, down from $148.0 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $271.0 million in Q2 2021, with the low at $119.7 million in Q2 2022.
  • Average Total Current Liabilities over 5 years is $167.8 million, with a median of $152.7 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities plummeted 55.83% in 2022, then soared 84.71% in 2023.
  • Over 5 years, Total Current Liabilities stood at $204.3 million in 2021, then plummeted by 32.84% to $137.2 million in 2022, then rose by 13.63% to $155.9 million in 2023, then increased by 5.26% to $164.1 million in 2024, then fell by 18.46% to $133.8 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $133.8 million, $148.0 million, and $199.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.